Saturday, July 04, 2026 · Claude + Codex (GPT-5.5), independent passes
Watchlists built by the rules: Day = Trend Join Long · Swing = gap-up + real catalyst
Deterministic criteria decide watchlist membership. Both AIs judge quality independently. RVOL note: yfinance reports approximately 0 premarket volume -- the rvol field is full-day relative volume and understates true premarket RVOL. Not financial advice.
Summary
The tape: Dow +1.14% to 52,900, S&P flat at 7,483, Nasdaq -0.80%, Russell -0.55% into the July 4th holiday close. VIX at 16.15 and falling -- fear is not elevated. Dollar flat, oil flat. Rate data unavailable (holiday data gap). Biotech and defense ran; crypto-adjacent names and anything that had already run hard got sold.
The catch: Both watchlists are mechanically empty -- markets are closed and today_open is null across all 12 gappers. Monday July 7th is the real test. Codex called it plainly: "this is a closed-market or stale scan." MRNA is the one both brains flagged independently as a sell-the-news trap.
Two-brain verdict: Both brains ran. Neither has a day trade. On swings, Codex gives GPC a Med but flags 34% prior run as priced-in. Claude holds GPC as the strongest Monday candidate but mechanical-only. They agree on all four trap calls: KEEL (sell-the-news), IREN (bad-news), MRNA (priced-in/extended), SLBT (no real catalyst). Full breakdown in the two-brains section below.
📊 Pre-Market Gappers
All 12 tickers that passed abs gap >= 4%, price >= $3, sorted by absolute gap descending.
| Ticker | Gap % | Price | Mkt Cap | Catalyst Headline |
|---|---|---|---|---|
| SLBT | +34.61% | $5.99 | $3.36B | No confirmed catalyst ("Top Midday Decliners" is a data artifact, not a driver) |
| PLBL | +18.20% | $10.26 | $3.76B | No confirmed catalyst |
| KEEL | -14.68% | $4.59 | $2.77B | Keel Infrastructure (KEEL) Completes Digital Shift And Joins The Russell 3000 |
| GPC | +12.92% | $132.57 | $18.44B | GPC Stock Pops 13%, ORLY Falls 5% -- O'Reilly Makes Cash Bid For Genuine Parts' $10B Auto Unit |
| SLS | +12.89% | $14.98 | $2.95B | Sellas Life (SLS) Climbs to Record High on Acquisition Buzz |
| CAR | +11.23% | $163.44 | $5.77B | Avis Wins $650 Million From Hedge Fund That Bet Big on Its Stock |
| AVAV | +10.70% | $190.89 | $9.66B | AeroVironment Stock Jumps. Sometimes Disabling Drones Is Worth More Than Making Them. (Barron's) |
| IREN | -10.39% | $38.82 | $13.87B | IREN Stock Heads For Ninth Straight Loss: $50M-A-Year NBA Spends, $788M Co-Founder Pay Packet Leave Retail Unimpressed |
| NKTR | +10.33% | $71.04 | $2.40B | NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema |
| BB | -10.15% | $11.51 | $6.75B | How BlackBerry is unlocking new potential in pivot from devices to software |
| MRNA | +10.01% | $79.76 | $31.65B | Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? |
| IMNM | +9.87% | $23.61 | $2.67B | Immunome, Inc. (IMNM) Reports Submission of an NDA for Varegacestat in Desmoid Tumors |
☀️ Day Trading Watchlist
Flag rule: gap > 3% vs prev close, price > $3, market cap > $1B, RVOL > 1.5, price > prior-day high. Setup: Trend Join Long (54.6% win rate, PF 1.59, 280 trades).
No day-eligible tickers this session.
today_open is null across all 12 gappers -- July 4th US holiday, no intraday bar. Both brains agree: no day trades today, mechanical reason not a quality reason. Recheck Monday premarket.
| Ticker | Catalyst | Levels (live) | Plan (Trend Join) | 🤖 Codex | Conv. |
|---|---|---|---|---|---|
| -- | No eligible names today | Holiday -- today_open null | Recheck Monday 7/7 | No day trades today. All today_open null. | -- |
📈 Notable Swing Watchlist
Flag rule: gap >= 8%, price > $3, open > prior-day high, open > 200-day SMA, market cap >= $800M, real catalyst. Backtest: 57.6% win rate / PF 5.34 news catalyst, 44.7% / PF 2.57 earnings catalyst.
No swing-eligible tickers this session.
Same holiday mechanic -- today_open null means open vs prior-day high and open vs 200-day SMA cannot resolve. Monday candidates if gaps hold: GPC (both brains watching), IMNM (Codex Low conviction, Claude watch-only).
| Ticker | Catalyst (headline) | Trend context | Idea | 🤖 Codex | Conv. |
|---|---|---|---|---|---|
| -- | No eligible names today | Holiday -- today_open null | Recheck Monday 7/7 | No swing qualifies mechanically today. | -- |
📉 Market Trends of the Day
- Biotech is the dominant theme -- both brains agree. Four of 12 gappers are biotech or pharma (MRNA, NKTR, SLS, IMNM). FDA approval cycle and M&A speculation are bidding up the sector broadly. Codex called it selective risk appetite, not broad.
- Defense spending is getting priced in. AVAV +10.7% on a Pentagon counter-drone contract. The use case is proven in active conflicts and defense budgets are expanding. Codex gave it Low conviction due to structural downtrend (price well below 200-day SMA at $254).
- M&A premium is alive. GPC and SLS both moved on deal activity. The market is pricing in probability, not certainty -- that unwinds fast if a deal falls through.
- Crypto-adjacent and over-extended names are getting sold. IREN (-10.4%), BB (-10.2%). Codex noted Nasdaq and Russell both red; it is the right tape to be selling extended names, not buying them.
📊 Technical Signals for Today
- S&P flat, Dow +1.14%, Nasdaq -0.80% -- rotation, not breakout. Both brains noted the divergence. Money is moving into old-economy names (GPC, CAR) out of growth. Watch whether this continues Monday or snaps back.
- VIX 16.15, down 2.65% -- fear is not elevated. Codex: "risk appetite is selective, not broad." Good backdrop for high-quality catalysts; a poor one for names with thin or speculative catalysts.
- Russell -0.55% -- small caps not confirming the Dow's strength. First signal of rotation if it continues. Several gappers (KEEL, SLBT, PLBL) are small-cap and that's a headwind.
- Dollar flat, oil flat -- no macro noise. Individual stock catalysts carry full weight Monday.
💰 Economic Data, Rates and the Fed
Light data day -- no high-impact USD events scheduled.
July 4th is a US federal holiday. econ_calendar.today is empty.
Rates from market snapshot:
| Instrument | Last | Change |
|---|---|---|
| US 10Y Yield (^TNX) | Unavailable | Data gap (holiday) |
| US 3M Yield (^IRX) | Unavailable | Data gap (holiday) |
| Dollar (DXY) | 100.857 | -0.0% |
| WTI Oil | $68.78 | +0.13% |
| VIX | 16.15 | -2.65% |
📅 Coming Up
No high-impact USD events scheduled for Sunday July 5th.
Notable earnings from the gapper list:
| Ticker | Next Earnings | Notes |
|---|---|---|
| GPC | July 21, 2026 | O'Reilly bid will dominate the call -- pre-earnings caution |
| CAR | July 29, 2026 | Post-settlement guidance on fleet and pricing |
| MRNA | July 31, 2026 | Key after a 70%+ run -- guidance miss risk is elevated |
| NKTR | August 6, 2026 | Clinical data expected before this -- binary event |
| IMNM | August 6, 2026 | NDA filed -- FDA clock starts |
| KEEL | August 10, 2026 | First print after Russell inclusion |
| SLS | August 11, 2026 | Phase 3 data still pending -- high-risk binary |
| IREN | August 27, 2026 | First print after co-founder comp controversy |
| AVAV | September 2, 2026 | Pentagon contract impact shows here |
| BB | September 24, 2026 | Software pivot results -- long way out |
| SLBT | No date available | -- |
| PLBL | No date available | -- |
🚫 Skips and Traps
| Ticker | Gap % | Why Skipped / Trap Flag |
|---|---|---|
| SLBT | +34.61% | Mystery gap -- both brains skip. Claude: "Top Midday Decliners" is a data artifact, not a catalyst. Codex: "Generic headline is not a real catalyst despite catalyst_found true." 34% gap with no real headline is a hard pass. |
| PLBL | +18.20% | No catalyst -- both brains skip. catalyst_found: false. Codex: "full stop." No further analysis. |
| KEEL | -14.68% | TRAP: Sell-the-news -- both brains agree. Down 14.7% on Russell 3000 inclusion. Codex: "likely sell-the-news and fighting weak Nasdaq/Russell tape." Claude: "retail chasers are providing exit liquidity for whoever bought the rumor." |
| GPC | +12.92% | Mechanical hold -- Claude watch, Codex Med swing. Real M&A catalyst (O'Reilly $10B bid). Codex gives Med but flags 34% prior run as priced-in risk. Claude holds it as the strongest Monday setup if open clears prior-day high ($135.44) and 200-day SMA ($118.21). Both waiting for Monday open. |
| SLS | +12.89% | Mechanical hold, elevated risk -- both cautious. Codex: "acquisition buzz and trial odds are not fresh enough, stock is far above 200-day, clear priced-in risk after record H1." Claude: starter-only if it qualifies Monday, acquisition buzz is not a confirmed deal. |
| CAR | +11.23% | Mechanical hold -- Codex skip, Claude hold. Codex: "rvol is weak and the move looks extended, sell-the-news risk." Claude: real catalyst ($650M settlement), but price right at 200-day SMA ($157.95), needs a clean Monday open. Split read -- size down if it qualifies. |
| AVAV | +10.70% | Mechanical hold, trend caution -- both flag. Codex: Low conviction, "below 200-day and already on a five-day green spell." Claude: "price ($190.89) is well below the 200-day SMA ($254.33) -- structural downtrend." Both note the Pentagon catalyst is real but trend context is poor. |
| IREN | -10.39% | TRAP: Bad-news dilution -- both brains agree. Codex: "Bad-news setup: massive founder equity deal, stock grants, pay packet controversy, ninth straight loss." Claude: "do not catch this falling knife." Red candle, bad news, no ambiguity. |
| NKTR | +10.33% | Mechanical hold, binary risk -- Codex skip, Claude watch. Codex: "upcoming clinical data is anticipation, not a clean event, with insider sale and weak rvol. Priced-in after 160% yearly move." Claude: trend is OK (price above 200-day), but catalyst not confirmed yet. Codex is more bearish here. |
| BB | -10.15% | Codex skip, Claude unclear. Codex: "Prior Q1 beat is stale, stock had a 243% rally, current move is red. Sell-the-news unwind." Claude: no clear new catalyst, profit-taking after 243% run. Both land on skip but Codex has the cleaner read. |
| MRNA | +10.01% | TRAP: Priced-in / extended -- both brains agree, hard skip. Codex: "FDA vote is real but stock is up more than 70% in a month and Wall Street target risk is explicit. Priced-in, sell-the-news risk." Claude: "if you weren't in before the vote, you are the exit." Full agreement. 🔴 |
| IMNM | +9.87% | Mechanical hold -- Codex Low, Claude watch. Codex: "NDA filing and Phase 3 success, above 200-day, but biotech move is modest and rvol is only average." Claude: prior 12.7% drop on Phase 3 data means clinical story is not cleanly resolved. Both say watch, neither says buy. |
🤖 Where the Two Brains Landed
Agreement (trade the overlap): Both brains hard-skip SLBT, PLBL, KEEL, IREN, and MRNA -- the four trap calls and the two no-catalyst names. Those are the cleanest signals in this packet: five names where neither brain has any interest. On the positive side, both are watching GPC for Monday. That is the overlap setup to track.
Rules vs discretion: Codex gave GPC a Med swing conviction despite no qualifying flag (today_open null). The deterministic rules say wait; Codex says the catalyst and technicals are strong enough to pre-flag it. Claude agrees directionally but stays mechanical: wait for Monday open. Where they split is CAR -- Codex calls it a skip (weak RVOL, sell-the-news risk), Claude is a hold. If CAR qualifies Monday, size it down; the brains are not aligned.
Claude's sharp catch: The MRNA priced-in trap. The headline in the packet literally says sell-side targets imply 44% downside -- that is not a subtle signal, it is the case against the trade embedded in the catalyst data itself. Reading the headline critically rather than just noting "FDA catalyst" is the call that matters here.
Codex's sharp catch: BB. Codex explicitly called it a "sell-the-news unwind" of a prior Q1 beat -- a stale earnings catalyst being unwound after a 243% run. Claude flagged it as unclear with no new catalyst. Codex was more precise: it knows exactly what the selling is. That context is useful if BB bounces Monday; Codex's read is that any bounce is still in a sell-the-news regime, not a fresh setup.
Trade where they agree. Where they disagree, stand down or size down. Never average the two views into a blended number.